Vector Smart Object3

It's Time TO CHALLENGE
Our Understanding of TDT
Red blood cells

Transfusion-Dependent β-Thalassemia (TDT) is a severe, progressive, genetic disease that impacts patients for life.1,2

TDT is the most severe form of beta-thalassemia, characterized by severe anemia and lifelong transfusion dependence which leads to iron overload, and can result in serious comorbidities and reduced survival. It's time to challenge our understanding of TDT and consider its genetic defect when caring for patients with beta‑thalassemia.1,2,3

Consider The Genetic Defect of TDT

There is an opportunity to explore additional options
that can correct the genetic defect in TDT.

Patients with TDT require
lifelong transfusions for
survival1

Chronic transfusion therapy enables survival, but only intermittently addresses symptoms and can lead to serious complications.1

Learn How

Allogeneic HSCT can potentially
correct the genetic deficiency
in TDT1,4,5

While it may give patients the opportunity to be thalassemia-free, HSCT is mostly limited to pediatric patients with HLA-matched donors.1,4,5

Discover Why

Quality of life is
significantly compromised
in patients with TDT6,7

Lifelong dependency on transfusions and ongoing supportive care can be physically and psychologically demanding on beta-thalassemia patients and caregivers.6,7

Understand More

Register now to receive resources to help support your TDT patients, invites to future webinars, and additional information about beta‑thalassemia.

Register for Resources
Life with beta-thalassemia

Help patients better understand the current impact TDT has on their lives, set goals, and plan for the future.

Visit LifeWithBetaThal.com
For Patient Resources
man walking

Actor portrayals throughout. Not real patients.

Take the Beta-Thalassemia Challenge

Current Thalassaemia International Federation (TIF) treatment guidelines for transfusion-dependent beta-thalassemia (TDT) recommend that:

D.

Current TIF guidelines for TDT recommend lifelong transfusions, typically every 2 to 5 weeks, in patients who meet the following criteria:1
· Confirmed diagnosis of thalassemia
· Hemoglobin level (Hb) <7 g/dL on 2 occasions, >2 weeks apart (excluding all other contributory causes such as infections)
OR
· Clinical criteria irrespective of hemoglobin level:
 · Hemoglobin > 7 g/dL with any of the following:
  · Facial changes
  · Poor growth
  · Fractures
  · Clinically significant extramedullary hematopoiesis

Share: